Epitope Structure of the Bordetella pertussis Protein P.69 Pertactin, a Major Vaccine Component and Protective Antigen
Open Access
- 1 July 2004
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (7) , 3716-3723
- https://doi.org/10.1128/iai.72.7.3716-3723.2004
Abstract
Bordetella pertussis is reemerging in several countries with a traditionally high vaccine uptake. An analysis of clinical isolates revealed antigenic divergence between vaccine strains and circulating strains with respect to P.69 pertactin. Polymorphisms in P.69 pertactin are mainly limited to regions comprised of amino acid repeats, designated region 1 and region 2. Region 1 flanks the RGD motif, which is involved in adherence. Although antibodies against P.69 pertactin are implicated in protective immunity, little is known about the structure and location of its epitopes. Here we describe the identification by pepscan analysis of the locations of mainly linear epitopes recognized by human sera and mouse monoclonal antibodies (MAbs). A total of 24 epitopes were identified, and of these only 2 were recognized by both MAbs and human antibodies in serum. A number of immunodominant epitopes were identified which were recognized by 78 to 93% of the human sera tested. Blocking experiments indicated the presence of high-avidity human antibodies against conformational epitopes. Human antibodies against linear epitopes had much lower avidities, as they were unable to block MAbs. Pepscan analyses revealed several MAbs which bound to both region 1 and region 2. The two regions are separated by 289 amino acids in the primary structure, and we discuss the possibility that they form a single conformational epitope. Thus, both repeat regions may serve to deflect the immune response targeted to the functional domain of P.69 pertactin. This may explain why the variation in P.69 pertactin is so effective, despite the fact that it is limited to only two small segments of the molecule.Keywords
This publication has 32 references indexed in Scilit:
- Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: Efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolatesVaccine, 2004
- Bordetella pertussisProtein Pertactin Induces Type‐Specific Antibodies: One Possible Explanation for the Emergence of Antigenic Variants?The Journal of Infectious Diseases, 2003
- Adaptation of Bordetella pertussis to Vaccination: A Cause for Its Reemergence?Emerging Infectious Diseases, 2001
- Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine1Financial support for the present study was provided by the Institut Pasteur Fondation and SmithKline Beecham Biologicals. All animal studies were conducted in accordance with the French and Belgian national legislative guidelines for animal experimentation.1Vaccine, 1999
- Temporal Trends in the Population Structure ofBordetella pertussisduring 1949–1996 in a Highly Vaccinated PopulationThe Journal of Infectious Diseases, 1999
- Structure of Bordetella pertussis virulence factor P.69 pertactinNature, 1996
- Structural aspects of antibody-antigen interaction revealed through small random peptide librariesMolecular Diversity, 1996
- Crystallographic Characterization of Pertactin, a Membrane-associated Protein from Bordetella pertussisJournal of Molecular Biology, 1994
- Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity.The Journal of Experimental Medicine, 1990
- Serum IgA antibody to Bordetella pertussis as an indicator of infectionJournal of Medical Microbiology, 1983